Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
Teva launches generic EpiPen in the U.S. | Fierce Biotech
How Mylan tried to keep Teva from selling a generic EpiPen
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Generic Drugmakers Mylan and Teva Face Antitrust Complaint
Drugmaker Teva makes $40B bid for rival Mylan
20 States Accuse Generic Drug Companies of Price Fixing - The New York Times
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Mylan rejects Teva takeover bid as too low | Mint
Teva's recall of U.S.-made drugs latest example of contamination fears in generic marketplace; report says Lilly, Pfizer and former Mylan plant in Morgantown have been cited in the past | WV News
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Lawmakers to Teva, Mylan: Stop stonewalling our price-fixing probe | Fierce Pharma
Teva-Makes-Hostile-Bid-Acquire
Valsartan recall expands to Mylan, Teva products | Fierce Pharma
Teva makes $40B offer for Mylan
Teva, Mylan, Sandoz and Aurobindo hit with patent suit
Mylan surges, Teva slumps after FDA approves Copaxone copy | Reuters.com
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Teva makes $40 billion offer for Mylan
Teva Offers to Buy Mylan for $40 Billion - WSJ
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
